Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report

Mult Scler. 2018 Jul;24(8):1131-1133. doi: 10.1177/1352458517741191. Epub 2018 Apr 30.

Abstract

Background: Rebound phenomena after discontinuation of different treatments for relapsing-remitting multiple sclerosis (RRMS) have previously been described. Systematic database research in PubMed did not show any report with relapse directly associated with dimethyl fumarate (DMF) cessation.

Case presentation: Here, we report on a 38-year-old Caucasian male patient suffering from a relatively mild course of RRMS who developed a fulminant clinical rebound 2 months after discontinuation of DMF therapy. Radiological alterations presented impressively with primarily spinal involvement. The patient received intensive care and multiple immunomodulating therapies.

Conclusion: We report on this case to raise neurologist's awareness of complications of basic therapy discontinuation in RRMS.

Keywords: Multiple sclerosis; clinical rebound; dimethyl fumarate cessation; dimethyl fumarate discontinuation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dimethyl Fumarate / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / pathology*
  • Recurrence
  • Spinal Cord / pathology

Substances

  • Immunosuppressive Agents
  • Dimethyl Fumarate